Navigation Links
Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
Date:2/26/2008

athway - minimizes the effect of the cancer's local immunosuppressive defenses.

About Non-Small Cell Lung Cancer (NSCLC)

In the United States, lung cancer is the second most frequent cancer in both men (next to prostate cancer) and women (next to breast cancer). It remains the major cause of cancer death, killing more people than breast cancer, prostate cancer and colorectal cancer combined, and accounting for almost 30% of all cancer-related deaths.

NSCLC accounts for approximately 80% of all new lung cancer cases, with approximately 150,000 patients in the United States and 300,000 patients in Europe diagnosed each year. Most patients diagnosed with NSCLC have late- stage disease (Stage IIIB or IV), which is not surgically resectable. The current U.S. standard of care for these patients is systemic chemotherapy. Even with the available therapy, the five-year survival rate for these patients is less than 3%.

About Agennix

Agennix is a private biotechnology company developing a first-in-class molecule with activity in several types of cancer and in other indications with unmet medical needs. This molecule, talactoferrin, is a targeted dendritic cell activator with a novel mechanism of action. Agennix is preparing to initiate Phase 3 trials in two NSCLC indications (talactoferrin in combination with chemotherapy in previously untreated patients and talactoferrin monotherapy in patients who have failed two or more previous therapies), a Phase 2b trial in renal cell cancer, and Phase 2 trials in other indications. Talactoferrin's potential advantages in NSCLC and in other tumor types include its promising anti-tumor activity, its well tolerated safety profile including a reduction of some chemotherapy toxicities, its oral route of administration, and its apparent usefulness in multiple tumor types both as a single agent and in combination with other drugs. Agennix retains all of the commercial and economic rights to talactoferrin for
'/>"/>

SOURCE Agennix
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
2. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
3. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
4. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
5. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
6. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
7. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
8. Outcomes Vary for Prostate Cancer Patients Choosing Surgery; Overall, No Treatment Proven Superior
9. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
10. Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
11. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015  CytomX Therapeutics, Inc., a biopharmaceutical ... today announced the filing of a registration statement on ... (SEC) relating to a proposed initial public offering of ... offered and the price range for the offering have ... common stock under the symbol "CTMX" on the NASDAQ ...
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Originally discovered by Welfide (Mitsubishi ... Industries, Ltd) as an inflammatory drug, pranoprofen was ... Co., Ltd under the trade name of pranopulin ...
(Date:8/28/2015)... -- Research and Markets ( ... "12th Annual Report and Survey of Biopharmaceutical ... offering. The 2015 12th Annual Report ... is the most recent study of biotherapeutic developers ... capacity and production. The report contains the industry,s ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Pranoprofen Market, 2010-2019 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2
... 2011 Covance Inc. (NYSE: CVD ) today ... Healthcare Conference on Thursday, February 24, 2011 at 10:00 a.m. ... at www.covance.com .  In order to register and download ... Covance, with headquarters in Princeton, New Jersey, is one ...
... IRVINE, Calif., Feb. 22, 2011 Endologix, Inc. (Nasdaq: ... disorders, today announced financial results for the three and twelve ... Endologix President and Chief Executive Officer, said, "We made tremendous ... quarter of 2010.  Revenue grew by 41% over the corresponding ...
Cached Medicine Technology:Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference 2Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 2Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 3Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 4Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 5Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 6Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 7Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 8Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 9Endologix Reports 41% Fourth Quarter 2010 Revenue Growth 10
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College ... the student experience as part of the EDUCAUSE - Next Generation Learning Challenges 2015 ... This is the third Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of ... for the position they are applying for, they are unable to pass the initial ... considering altering drug testing policies in order to be able to hire long-term, skilled ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Understanding the FDA’s Position and Best Practices for Compliance, **Presented by FDAnews ... This workshop, chaired by internationally renowned expert Fubin Wu, has been specifically ...
(Date:8/28/2015)... Manistee, Michigan (PRWEB) , ... August 28, 2015 ... ... or alcohol abuse, or those who might personally be struggling with chemical dependency, ... blog post from Best Drug Rehabilitation, a results-driven holistic treatment center for addiction ...
(Date:8/28/2015)... ... 28, 2015 , ... Drugs and alcohol abuse by employees ... new approach on solutions in his new book ":Unraveling The Psychological Mystery of ... together for meaningful group meetings. "This would educate the employees on not ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3
... Aug. 3 Blue Cross and Blue Shield of Georgia ... administration of the H1N1 (swine flu) vaccine when it becomes ... be covered for members whose benefit plans provide coverage for ... coverage of seasonal flu vaccine administration for those whose health ...
... A new class of antibody drugs may provide a powerful ... but specialists need to be alert for the possibility of ... Journal of AAPOS (American Association for Pediatric Ophthalmology ... of Santa Barbara, Calif., discusses issues related to the use ...
... of synthetic biology will, in the medium term, open up ... with engineering principles. This will facilitate the development, not only ... new materials. Early-stage dialogue with the public on the natural ... success and acceptance of this new technology. With a joint ...
... 3 Medial Saude S/A,(BOVESPA: MEDI3) (MEDIAL SAUDE) announces the following webcast: , , ... When: Friday, August 14, 2009 at 12:00 PM ET, ... Live over the Internet -- Simply log on to the web at the, ... Conference call dial-in phone numbers:, Toll-free from the US: ...
... , SILVER SPRING, Md., Aug. 3 Four ... session of ongoing couples therapy can greatly increase chances for ... The largest clinical trial with couples to date, it shows ... feedback technique were 46.2 percent less than that of couples ...
... INCLINE VILLAGE, Nev., Aug. 3 PDL BioPharma, Inc. (PDL) ... E. ("Barry") Selick, Ph.D., to the Company,s Board of Directors. , ... and his extensive knowledge of PDL,s humanization technology will allow him ... seek to maximize the value of our antibody humanization patents and ...
Cached Medicine News:Health News:BCBSGA Announces Decision to Cover H1N1 Vaccine Administration 2Health News:Anti-growth factor drugs raise hope and concern for treatment of children's eye diseases 2Health News:Synthetic biology -- opportunities and risks 2Health News:Synthetic biology -- opportunities and risks 3Health News:Therapy Technique Cuts Divorce/Separation Rate By Nearly 50 Percent 2Health News:PDL BioPharma Elects Barry Selick to Its Board of Directors 2
... capture the patient`s exhaled heat and moisture ... Small and compact, they are specially treated ... on the tidal volume requirements, select either ... adult HCH is ideal for patient tidal ...
Combination heat and moisture exchanger and bacterial/viral filters for Anesthesia and Respiratory applications....
Combination heat and moisture exchanger and bacterial/viral filters for Anesthesia and Respiratory applications....
HME only...
Medicine Products: